ARVINAS, INC. Restructuring Charges
ARVINAS, INC. (ARVN) reported Restructuring Charges of $1.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-08-04
- ARVINAS, INC. restructuring charges for the quarter ending 2026-06-30 was $1.60M, a 60.00% increase year-over-year.
- ARVINAS, INC. restructuring charges for the quarter ending 2026-03-31 was $1.10M.
- ARVINAS, INC. restructuring charges for the quarter ending 2025-12-31 was $3.00M.
- ARVINAS, INC. restructuring charges for the quarter ending 2025-09-30 was -$200.00K.
- ARVINAS, INC. restructuring charges for fiscal 2025 was $3.70M.
- ARVINAS, INC. restructuring charges for fiscal 2024 was $0.00.
- ARVINAS, INC. restructuring charges for fiscal 2023 was $0.00.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.60M 10-Q · filed 2026-08-04 | $2.70M 10-Q · filed 2026-08-04 | $5.70M derived: sum of 3 quarters · filed 2026-08-04 | $5.50M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $1.10M 10-Q · filed 2026-05-11 | $4.10M derived: sum of 2 quarters · filed 2026-05-11 | $3.90M derived: sum of 3 quarters · filed 2026-05-11 | $4.90M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $2.80M derived: sum of 2 quarters · filed 2026-02-24 | $3.80M derived: sum of 3 quarters · filed 2026-08-04 | $3.70M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$200.00K 10-Q · filed 2025-11-05 | $800.00K derived: sum of 2 quarters · filed 2026-08-04 | $700.00K 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $1.00M 10-Q · filed 2026-08-04 | $1.00M 10-Q · filed 2026-08-04 | ||
| 2024-12-31 | $0.00 10-K · filed 2026-02-24 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |